Chromogenic Factor VIII Inhibitor Bethesda Profile, Plasma
Use
The Chromogenic Factor VIII Inhibitor Bethesda Profile is useful for detecting the presence and quantifying the titer of specific inhibitors directed against coagulation factor VIII in patients being treated with the antibody emicizumab (Hemlibra). It helps in identifying inhibitors that target factor VIII, which can lead to severe bleeding complications. This test is specifically beneficial for patients who may have developed alloimmune inhibitors against infused factor VIII or autoimmune inhibitors during conditions such as pregnancy or autoimmune diseases.
Special Instructions
Not provided.
Limitations
This test will not detect inhibitors directed against other clotting factors besides factor VIII, nor is it capable of detecting the presence of lupus anticoagulants. Specimen contamination with excess heparin or hemodilution can lead to erroneous results. It requires careful handling and processing to avoid these issues.
New York Approved
Methodology
Other (Chromogenic)
Biomarkers
Factor VIII Inhibitor
Analyte
LOINC Codes
- 95121-0 - Fact VIII Act + Inhib Pnl PPP Chro
- 93450-5 - Fact VIII Inhib PPP Chro-aCnc
- 95122-8 - Fact VIII Inhib PPP Chro-Imp
- 18771-6 - Provider signing name
- 49865-9 - Fact VIII Act/Nor PPP Chro
Result Turnaround Time
3-4 days
Related Documents
For more information, please review the documents below
Specimen
Plasma
Volume
2 mL
Minimum Volume
Not provided
Container
Plastic vials
Collection Instructions
1. Collect specimens prior to factor replacement therapy. 2. If collecting through a port/line, ensure appropriate wastage. 3. Follow guidelines for double centrifugation before freezing. 4. Freeze immediately, ideally at -40°C.
Storage Instructions
Freeze at -20°C or below, ideally at -40°C for longer stability.
Causes for Rejection
Gross hemolysis, lipemia, icterus, or IV heparin contamination will result in rejection.
Stability Requirements
| Temperature | Period |
|---|---|
| Frozen | 14 days |